688105 Nanjing Vazyme Biotech
- 24.95
- +0.45+1.84%
Nanjing Vazyme Biotech News
Novi Zan: Novi Zan\'s announcement on increasing the amount of temporarily idle funds to purchase wealth management products
Novi Zan: Novi Zan\'s announcement on proposed foreign investment to establish a holding company and related transactions
Novi Zan\'s announcement on increasing the amount of temporarily idle funds to purchase wealth management products
Huatai United Securities Co., Ltd. inspection opinions on the joint investment and establishment of holding subsidiaries and related transactions between Nanjing Novizan Biotechnology Co., Ltd. and related parties
Novi Zan\'s announcement on proposed foreign investment to establish a holding company and related transactions
Novi Zan: Novi Zan\'s progress announcement on the repurchase of the company\'s shares through centralized bidding transactions
Novi Zan\'s announcement on the departure of core technical staff
Notice from Novartis on the voluntary disclosure of fully-owned subsidiary's acquisition of medical instruments registration certificate.
Notice of Resolutions of the 2023 Annual Shareholders' Meeting of NuoWeiZan
Legal Opinion of Tianyuan Law Firm regarding the 2023 Shareholders' Meeting of Nanjing Novozymes Biotechnology Co., Ltd. in Peking
2023 Annual General Meeting of Shareholders Meeting Materials
Novi Zane's Notice on Convening the 2023 Annual General Meeting of Shareholders
Novi Zan's Announcement on Voluntary Disclosure of Wholly-Owned Subsidiaries Signed Cooperation Agreements
2024 “Improve Quality, Increase Efficiency, and Focus on Return” Special Action Plan
Novi Zan's announcement on preparation for impairment of accrued assets and write-off of assets for 2023
Novi Zan's announcement on the extension of fund-raising investment projects
Novi Zan's announcement on revisions to the “Articles of Association” and some internal governance systems
“Articles of Association” (revised in April 2024)
Rules of Procedure for Board of Directors (Revised April 2024)
“Rules of Work for the Audit Committee of the Board of Directors” (revised in April 2024)
Analysis
Price Target
No Data
No Data